博晖创新子公司人凝血因子Ⅷ获得药品注册证书

Core Viewpoint - The company BoHui Innovation (300318.SZ) announced that its subsidiary BoHui Biopharmaceutical (Hebei) Co., Ltd. has received the Drug Registration Certificate from the National Medical Products Administration for its product Human Coagulation Factor VIII, which is significant for treating hemophilia A and acquired Factor VIII deficiency [1] Group 1 - The newly approved Human Coagulation Factor VIII is designed to correct coagulation dysfunction caused by a lack of this factor, primarily used for the prevention and treatment of bleeding symptoms in hemophilia A patients [1] - The approval of the Drug Registration Certificate enhances the company's product line and is a crucial step for BoHui Biopharmaceutical in improving plasma utilization efficiency [1]